PHILADELPHIA, Sept. 17, 2025 (GLOBE NEWSWIRE) --

Applied Therapeutics, Inc. (NASDAQ: APLT) – Class Action Reaches Settlement:

Grabar Law Office is investigating claims on behalf of shareholders of Applied Therapeutics. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

A securities fraud class action against Applied Therapeutics, Inc. (NASDAQ: APLT) and certain of its officers has reached a settlement.

If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.

WHY? As alleged in a recently filed securities fraud class action complaint, Applied Therapeutics, Inc. (NASDAQ: APLT), through certain of its officers, provided positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of Applied Therapeutics’ Phase III INSPIRE trial; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study. The Complaint further alleges that such statements absent these material facts caused Plaintiff and other shareholders to purchase Applied Therapeutics’ securities at artificially inflated prices.

On August 25, 2025, the parties reported to the Court that they had agreed to settle the securities fraud class action.

WHAT YOU CAN DO NOW: If you purchased Applied Therapeutics (NASDAQ: APLT) shares prior to January 3, 2024, and still hold shares today, please visit https://grabarlaw.com/the-latest/applied-therapeutics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $APLT #AppliedTherapeutics

DoubleVerify Holdings, Inc. (NYSE: DV):

Grabar Law Office is investigating whether certain officers and directors of DoubleVerify Holdings, Inc. (NYSE: DV) breached their fiduciary duties owed to the company.

If you have held DoubleVerify Holdings, Inc. (NYSE: DV) shares since prior to November 10, 2023, and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/doubleverify-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.

Why? As alleged in an underlying securities fraud class action complaint, DoubleVerify (NYSE: DV), via certain of its officers, failed to disclose that: (a) DoubleVerify’s customers were shifting their ad spending from open exchanges to closed platforms, where the Company’s technological capabilities were limited and competed directly with native tools provided by platforms like Meta Platforms and Amazon; (b) DoubleVerify’s ability to monetize on Activation Services, the Company’s high-margin advertising optimization services segment, was limited because the development of its technology for closed platforms was significantly more expensive and time-consuming than disclosed to investors; (c) DoubleVerify’s Activation Services in connection with certain closed platforms would take several years to monetize; (d) DoubleVerify’s competitors were better positioned to incorporate AI into their offerings on closed platforms, which impaired DoubleVerify’s ability to compete effectively and adversely impacted the Company’s profits; (e) DoubleVerify systematically overbilled its customers for ad impressions served to declared bots operating out of known data center server farms; (f) DoubleVerify’s risk disclosures were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities; and (g) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.

What You Can Do Now: Current DoubleVerify (NYSE: DV) shareholders who have held DoubleVerify shares since prior to November 10, 2023, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/doubleverify-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. $DV #DoubleVerify

Elevance Health Inc. (NYSE: ELV):

Grabar Law Office is investigating claims on behalf of shareholders of Elevance Health Inc. (NYSE: ELV). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Elevance Health Inc. (NYSE: ELV) shares prior to April 18, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/elevance-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085, to learn more.

WHY? As alleged in a recently filed federal securities fraud class action complaint, Elevance Health Inc. (NYSE: ELV), through certain of its officers, represented to investors that they were closely monitoring cost trends associated with the redetermination process and that the premium rates Elevance was negotiating with states were sufficient to address the risk and cost profiles of those patients staying on Medicaid programs. In fact, sicker patients with higher acuity tended to remain on Medicaid after redetermination, leading to higher per-patient costs. This increase in cost was occurring at a rate that was not adequately reflected in Elevance’s rate negotiations with the states or in its financial guidance for 2024. As a result, the Complaint alleges Defendants’ positive statements concerning Elevance’s close monitoring of the redeterminations, the actuarial soundness of its rates and the prudence of its forecasts were materially misleading and/or lacked a reasonable basis.

WHAT YOU CAN DO NOW: If you purchased Elevance Health Inc. (NYSE: ELV) shares prior to April 18, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/elevance-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $ELV #Elevance

V.F. Corp. (NYSE: VFC):

Grabar Law Office is investigating claims on behalf of shareholders of V.F. Corp. (NYSE: VFC). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased V.F. Corp. (NYSE: VFC) shares prior to October 30, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased V.F. Corp. shares between October 30, 2023, to May 20, 2025, inclusive, you can participate in the class action. Please visit https://grabarlaw.com/the-latest/vfc-sahreholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085, to learn more.

WHY? According to a recently filed securities fraud class action complaint, V.F. Corp. (NYSE: VFC), through certain of its officers, disseminated materially false and misleading statements and/or concealed material adverse facts concerning the true state of V. F. Corp.'s turnaround plans. Specifically, it is alleged that V. F. Corp. announced its "Reinvent" strategy in 2023, to, among other things, attempt to revive the struggling Vans brand. But, almost two years after it announced the plan, V. F. Corp. said Vans had experienced significant growth deceleration and signaled the sales decline would continue in the subsequent quarters. As alleged, the company had told investors it would take time for the initiatives to take full effect, but that it expected to make progress "beginning quickly. “For the next several quarters, V. F. Corp. stated it was "encouraged" by the progress it was making on its turnaround strategy, and that the benefits of the inventory cleanup actions were starting to positively affect profitability. Then, on May 21, 2025, VFC announced Vans was performing below expectations. On that day, V.F. Corp. told investors Vans' overall performance was down 20% year-over-year in the fourth fiscal quarter after being down 8% in the prior quarter, according to the suit. The company attributed the results to low traffic at its stores and websites, and it said that challenges could continue into subsequent quarters.

WHAT YOU CAN DO NOW: If you purchased V.F. Corp. (NYSE: VFC) shares prior to October 30, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/vfc-sahreholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Alternatively, if you purchased V.F. Corp. shares between October 30, 2023, to May 20, 2025, inclusive, you can participate in the class action. $VFC #VFCorp

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com